SCHEMBL2447422

SCHEMBL2447422

Cn1cc(-c2ccnc(Oc3ccc(F)c(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)c3)n2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.55
AXL P30530 9/20 0.55
FLT3 P36888 6/20 0.48
PDGFRB P09619 5/20 0.48
CSF1R P07333 5/20 0.48
PDGFRA P16234 4/20 0.48
KDR P35968 8/20 0.47
NTRK1 P04629 3/20 0.47
TEK Q02763 2/20 0.47
NTRK3 Q16288 1/20 0.47
NTRK2 Q16620 1/20 0.47
RIPK2 O43353 2/20 0.45
ABL1 P00519 2/20 0.45
LCK P06239 2/20 0.45
LYN P07948 2/20 0.45
RET P07949 2/20 0.45
HCK P08631 2/20 0.45
BCR P11274 2/20 0.45
EPHA2 P29317 2/20 0.45
ABL2 P42684 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2409752 0.88 AXL (0.52) METAXLFLT3PDGFRBCSF1R
SCHEMBL3490670 0.86 AXL (0.54) METAXLFLT3PDGFRAKDR
SCHEMBL2444265 0.83 AXL (0.58) METAXLFLT3PDGFRBCSF1R
SCHEMBL27846589 0.82 KDR (0.54) KDRNTRK1TEK
SCHEMBL2411263 0.82 MET (0.64) METAXLFLT3PDGFRBCSF1R
SCHEMBL2439504 0.81 CSF1R (0.61) METAXLFLT3PDGFRBCSF1R
SCHEMBL2415429 0.80 MET (0.56) METAXLFLT3PDGFRBCSF1R
SCHEMBL5067404 0.79 CSF1R (0.41) METAXLFLT3PDGFRBCSF1R
SCHEMBL2444171 0.79 CSF1R (0.70) METAXLFLT3PDGFRBCSF1R
SCHEMBL2413329 0.79 MET (0.72) METAXLFLT3PDGFRBCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2365752-B1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2014-09-24 EP disclosed
US-8486951-B2 Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2013-07-16 US disclosed
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-03-28 US disclosed
US-8278331-B2 N-acyl ureas exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2012-10-02 US disclosed
EP-2365752-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, Llc (US) 2011-09-21 EP disclosed
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2010-05-13 US disclosed
WO-2010051373-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB MET 7/4885AXL 439/4885FLT3 15/4885
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB MET 7/4885AXL 441/4885FLT3 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.